Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Mol Neurobiol. 2021 Sep 28;58(12):6540–6551. doi: 10.1007/s12035-021-02560-1

Figure 2:

Figure 2:

Analgesia was higher in females during diestrus than during estrus; a within animal study design.

Females were each tested during their estrus phase and during their diestrus phase; analgesia and 30-min oxycodone plasma levels were assessed, both at a, b, c, 10 mg/kg (n=11 female rats) and d, e, f, 7.5 mg/kg (n= 11 female rats) oral oxycodone. Lines represent data within animal tested during their estrus phase and during their diestrus phase. a, analgesic-time curve at 10 mg/kg (FCycle(1,10) = 13.21, p=0.0046; Ftime(16,160) = 89.52, p<0.0001; FInteraction(16, 160) = 4.12, p<0.0001). b, analgesic AUC0-120 at 10 mg/kg, *p=0.0154. c, 30-min plasma oxycodone levels at 10 mg/kg, p=0.8793. d, analgesic-time curve at 7.5 mg/kg (FCycle(1,10) = 18.71, p=0.0015; Ftime(16,160) = 107.60, p<0.0001; FInteraction(16, 160) = 3.21, p<0.0001). e, analgesic AUC0-120 at 7.5 mg/kg, **p=0.0018. f, 30-min plasma oxycodone levels at 7.5 mg/kg, p=0.5932. Analgesic-time curves were assessed using two-way ANOVA with repeated measures by both factors. AUCs0-120 and 30-min plasma oxycodone levels were assessed using paired t-test.